View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 13, 2011

Alemtuzumab Shows Efficacy for Multiple Sclerosis

Sanofi-Aventis and its subsidiary, Genzyme, have reported positive top-line results from CARE-MS I, the first of two Phase II clinical trials of alemtuzumab in patients with relapsing-remitting multiple sclerosis. Alemtuzumab targets cell-surface glycoprotein CD52, and depletes the T-

By cms admin

Sanofi-Aventis and its subsidiary, Genzyme, have reported positive top-line results from CARE-MS I, the first of two Phase II clinical trials of alemtuzumab in patients with relapsing-remitting multiple sclerosis.

Alemtuzumab targets cell-surface glycoprotein CD52, and depletes the T- and B-cells that may be responsible for cellular damage in multiple sclerosis.

The two-year randomised, rater-blinded CARE-MS I trial enrolled 581 early, active relapsing-remitting multiple sclerosis patients. Those treated with alemtuzumab showed a 55% reduction in relapse rate compared to approved multiple sclerosis therapy Rebif.

The study also demonstrated that 8% of alemtuzumab treated patients had a sustained increase in their expanded disability status scale score versus 11% of those who received Rebif.

Sanofi-Aventis CEO Christopher Viehbacher said they the company was looking forward to the results from the ongoing CARE-MS II trial, which will provide clinical data in patients whose disease was not adequately controlled on other multiple sclerosis therapies.

The drug-associated adverse events observed included headache, rash, fever, nausea, flushing, hives, chills, upper respiratory and urinary tract infections and oral herpes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology